The ONCONEXT LIQUIDTM CNV test is a genome-wide next-generation sequencing (NGS)-based assay designed for detection of gains and losses (Copy Number Variations – CNVs) of large chromosome sections in the genome of cancer cells by analyzing circulating tumor DNA (ctDNA) from a plasma sample of patients. The identification of CNVs across the genome is a consequence of genomic instability (Copy Number Instability), hallmarks of cancer cells, and indicates tumor existence or progression.

The ONCONEXT LIQUIDTM CNV test is suitable for therapy monitoring for patients with chemotherapy or immunotherapy and for relapse monitoring after tumor resection.



ONCONEXT LIQUIDTM genetic tests by Genoma Group were planned for the study of somatic mutations ofcirculating tumor DNA (ctDNA) in peripheral blood in oncologic patients, or at high risk to become one.

The ctDNA study, also called liquid biopsy, is the most innovative instrument the oncologist can use today. Through Onconext LiquidTM, liquid biopsy by Genoma Group, the clinician can properly perfect the diagnosis and prognosis of the oncologic patient, and can detect in a high risk patient the presence of somatic mutations that, if they change significantly over time, may be indicative of the presence of tumor focus diagnosable, thanks to this technology, in a very early period.

Onconext LiquidTM do not replace tissue biopsy, which remain the gold standard for the first morphological/histological diagnosis and the main DNA source for the study of the genomic profile of the pathology, but confirms and deepens the information obtained.

Onconext LiquidTM is also the best substitute test of traditional biopsy in all those situations in which the latter finds a limited use in relation to its characteristics of invasiveness.


Invasive and expensive

Strongly influenced by tumor position

Representativeness limited by genomic heterogeneity

Sometimes difficult or impossible biopsy tissue sampling

Not usable if the primary tumor has been removed

It often needs preparation

The repetition of tissue sampling is subject to limitations

Often it needs adequate structures with specialised surgery area

It often needs long waiting times


Non-invasive with a good benefit/cost ratio

Independent from tumor position

Good representativeness of genomic heterogeneity

Simple and always accessible blood sampling

Can be used after surgery for early evaluation of residual disease or recovery

No preparation needed

The repetition of the blood sample is always possible

Sampling always performable in any sampling point

Rapid waiting times both for the sampling and for the report receiving

Useful tool for dynamic monitoring of the therapeutic response and resistance development

Comparison between traditional tissue biopsy and Onconext LiquidTM.

With ONCONEXT LIQUIDTM, liquid biopsy by Genoma Group is possible today, not only to confirm molecular information on tissue biopsy provided by classic invasive technique, but also to expand the result thanks to the greater representativeness of genomic heterogeneity provided by ctDNA (circulating tumor DNA in peripheral blood).

ONCONEXT LIQUIDTM benefits are not limited to the quality improvement of the information obtained, but they allow dynamic study with accessible costs and a good patient tolerance.

ONCONEXT LIQUIDTM tests are performed by a peripheral blood sample, and it’s sufficient a sample of 8-10 ML

ONCONEXT LIQUIDTM tests are available in two versions to meet every diagnostic need:


The ONCONEXT LIQUIDTM Monitor tests were planned for oncological use on patients who have already been diagnosed with tumor, with different diagnostic and clinical purposes:

  • Providing a tumor profiling for the correct application of precision medicine. OncoNext Liquid™Monitor tests can provide the oncologist with information that is useful to shape a personalised treatment plan
  • Monitoring the effectiveness of the recommended therapy by detecting the presence of mutations before and during treatment
  • Monitoring the residual disease and/or the presence of early relapse in the patient with known mutations in primary tumor, in particular in cases in which patients have undergone a tumor resection and/or are in remission period
  • Assisting the oncologist in choosing new treatment options when the patient develops resistance to the underway therapy
  • Providing an alternative method of biopsy when the tissue is difficult or impossible to reach, or when in addition to the primary site of the disease in metastatic phase, can be present unknown sites, or when tissue quantity obtained by traditional biopsy sample is not sufficient for molecular genotyping
  • Providing prognostic information
  • Being supportive for a patient admission to a Clinical Trial: it is an additional function of OncoNext Liquid™Monitor test, to outline the patient and his or her disease properly in order to identify any ongoing clinical trial in which the patient fall into eligibility criteria.

ONCONEXT LIQUIDTM Monitor tests include the study of specific panels custom-designed to meet the different diagnostic needs:

Download ONCONEXT LIQUIDTM  brochure




ONCONEXT LIQUIDTM Scan is a genetic test planned for oncologic use on patient at high risk of developing a tumor. The test detects the presence of somatic mutations (even before the tumor can be detected with traditional techniques) known as tumor “driver mutations”, as an innovative instrument in personalised surveillance programs.

Early diagnosis, in asymptomatic individuals, may allow more effective treatments with a consequent raise of the survival rate. Many types of tumor develop silently with local invasiveness and are clinically undetectable until reaching a considerable mass with subsequent diagnostic delay.

Onconext LiquidTM Scan, liquid biopsy by Genoma Group, dedicated to high oncological risk patients, allows detecting ctDNA spread in the bloodstream even from very small lesions.

Example of high risk people for which is useful to include ONCONEXT LIQUIDTM Scan in personalised surveillance programs:

  • Significant family history of tumor correlated in literature to mutations on genes in the investigated panel
  • Known genetic predisposition (germline mutation) for an inherited tumor
  • Personal history of smoking, or extended exposure to passive smoking
  • Extended exposure to carcinogenic agents such as: pollution, radiations, UV rays and manipulation of antiblastics
  • Prolonged treatments with hormonal therapies (fertility drugs, hormone replacement therapies containing progesterone)
  • Chronic or infectious diseases predisposing to tumor development

ONCONEXT LIQUIDTM Scan test was planned to detect somatic mutations on the main genes involved in the tumor development process.


    Name (required)

    Email (required)

    Choose the type of test you require


    I have read and accept Privacy Policy